banner



Home  ›  9 7 Zoll In Cm Ipad

9 7 Zoll In Cm Ipad

Written By Wednesday, September 28, 2022 Add Comment Edit
U.South. markets shut in 3 hours sixteen minutes

  • Due south&P 500

  • Dow 30

  • Nasdaq

  • Russell 2000

  • Crude Oil

  • Gilded

  • Silver

  • EUR/USD

  • 10-Yr Bond

  • GBP/USD

  • USD/JPY

  • BTC-USD

  • CMC Crypto 200

  • FTSE 100

  • Nikkei 225

InspireMD Commences Trading on Nasdaq-CM

Ticker to remain NSPR

TEL AVIV, State of israel, May 21, 2021 (Globe NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused past Carotid Artery Affliction (CAD), today appear that the Company'due south shares will commence trading on The Nasdaq Capital Market ("Nasdaq-CM"), today, May 21, 2021, nether the symbol NSPR.

InspireMD CEO Marvin Slosman said, "The trading of our shares on the Nasdaq Capital Market is a yet another very important step in the continued development of InspireMD equally we seek to create improved awareness of the Company, augment our shareholder base, and meliorate trading liquidity in our efforts to found a new standard of intendance in the treatment of carotid artery disease and stroke prevention."

Nearly InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® engineering science to make its products the manufacture standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.

Forward-looking Statements

This press release contains "frontward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future functioning, are based on certain assumptions and are subject area to various known and unknown risks and uncertainties, many of which are across the Company's command, and cannot exist predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market place credence of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an disability to secure regulatory approvals for the sale of our products, (four) intense competition in the medical device manufacture from much larger, multinational companies, (five) product liability claims, (6) product malfunctions, (vii) our express manufacturing capabilities and reliance on subcontractors for assist, (viii) insufficient or inadequate reimbursement by governmental and other 3rd party payers for our products, (nine) our efforts to successfully obtain and maintain intellectual belongings protection roofing our products, which may not exist successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and strange jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will demand to raise additional uppercase to run across our business requirements in the hereafter and that such majuscule raising may be costly, dilutive or difficult to obtain and (13) the fact that we conduct business concern in multiple foreign jurisdictions, exposing united states to foreign currency commutation rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may touch the realization of forwards-looking statements is set along in the Company'southward filings with the Securities and Commutation Commission (SEC), including the Company's Annual Written report on Class 10-Grand and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents gratis of accuse on the SEC'due south web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com

Core IR
investor-relations@inspiremd.com

9 7 Zoll In Cm Ipad,

Source: https://finance.yahoo.com/news/inspiremd-commences-trading-nasdaq-cm-123000911.html

Posted by: brownrive1996.blogspot.com

0 Response to "9 7 Zoll In Cm Ipad"

Post a Comment

Subscribe to: Post Comments (Atom)

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel